Effects of estrogen and the selective estrogen receptor modulator raloxifene on markers of inflammation in postmenopausal women.
Blum
A
A
Cardiology Branch, National Institute of Health, Bethesda, Maryland, USA.
Schenke
W H
WH
Hathaway
L
L
Mincemoyer
R
R
Csako
G
G
Waclawiw
M A
MA
Cannon
R O
RO
D002097:C-Reactive Protein / Q000032:analysis; D015815:Cell Adhesion Molecules / Q000097:blood*; D008078:Cholesterol, LDL / Q000097:blood; D018592:Cross-Over Studies; D004311:Double-Blind Method; D004966:Estrogens, Conjugated (USP) / Q000494:pharmacology; D005260:Female; D006801:Humans; D008074:Lipoproteins / Q000097:blood*; D008875:Middle Aged; D017698:Postmenopause / Q000097:blood*; D020849:Raloxifene Hydrochloride / Q000494:pharmacology*; D020845:Selective Estrogen Receptor Modulators / Q000494:pharmacology*
D015815:Cell Adhesion Molecules; D008078:Cholesterol, LDL; D004966:Estrogens, Conjugated (USP); D008074:Lipoproteins; D020845:Selective Estrogen Receptor Modulators; D020849:Raloxifene Hydrochloride; D002097:C-Reactive Protein